• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Chemotherapy and Targeted Therapy for Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That Is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Rapid Recommendation Update.

作者信息

Moy Beverly, Rumble R Bryan, Carey Lisa A

机构信息

Massachusetts General Hospital, Boston, MA.

American Society of Clinical Oncology, Alexandria, VA.

出版信息

J Clin Oncol. 2022 Sep 10;40(26):3088-3090. doi: 10.1200/JCO.22.01533. Epub 2022 Aug 4.

DOI:10.1200/JCO.22.01533
PMID:35926153
Abstract
摘要

相似文献

1
Chemotherapy and Targeted Therapy for Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That Is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Rapid Recommendation Update.人表皮生长因子受体2阴性转移性乳腺癌的化疗和靶向治疗：内分泌预处理或激素受体阴性患者的美国临床肿瘤学会指南快速推荐更新
J Clin Oncol. 2022 Sep 10;40(26):3088-3090. doi: 10.1200/JCO.22.01533. Epub 2022 Aug 4.
2
Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update.内分泌治疗后或激素受体阴性转移性乳腺癌的化疗与靶向治疗：美国临床肿瘤学会指南快速推荐更新
J Clin Oncol. 2023 Feb 20;41(6):1318-1320. doi: 10.1200/JCO.22.02807. Epub 2023 Jan 10.
3
Endocrine and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer-Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update.激素受体阳性、人表皮生长因子受体 2 阴性转移性乳腺癌的内分泌和靶向治疗-卡培他滨-氟维司群：ASCO 快速推荐更新。
J Clin Oncol. 2024 Apr 20;42(12):1450-1453. doi: 10.1200/JCO.24.00248. Epub 2024 Mar 13.
4
Testing for Mutations to Guide Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update.检测突变以指导激素受体阳性、人表皮生长因子受体 2 阴性转移性乳腺癌的治疗：ASCO 指南快速推荐更新。
J Clin Oncol. 2023 Jun 20;41(18):3423-3425. doi: 10.1200/JCO.23.00638. Epub 2023 May 17.
5
Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer-Cyclin-Dependent Kinase 4 and 6 Inhibitors: ASCO Guideline Rapid Recommendation Update.早期乳腺癌的最佳辅助化疗和靶向治疗——细胞周期蛋白依赖性激酶 4 和 6 抑制剂：ASCO 指南快速推荐更新。
J Clin Oncol. 2024 Jun 20;42(18):2233-2235. doi: 10.1200/JCO.24.00886. Epub 2024 May 20.
6
Adjuvant PARP Inhibitors in Patients With High-Risk Early-Stage HER2-Negative Breast Cancer and Germline Mutations: ASCO Hereditary Breast Cancer Guideline Rapid Recommendation Update.高危早期HER2阴性乳腺癌和生殖系突变患者的辅助性聚（ADP-核糖）聚合酶抑制剂：美国临床肿瘤学会遗传性乳腺癌指南快速推荐更新
J Clin Oncol. 2021 Sep 10;39(26):2959-2961. doi: 10.1200/JCO.21.01532. Epub 2021 Aug 3.
7
Abemaciclib With Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Rapid Recommendation Update.阿贝西利联合内分泌治疗用于高危早期乳腺癌的治疗：美国临床肿瘤学会最佳辅助化疗和靶向治疗指南快速推荐更新
J Clin Oncol. 2022 Jan 20;40(3):307-309. doi: 10.1200/JCO.21.02677. Epub 2021 Dec 8.
8
Use of Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update.免疫检查点抑制剂帕博利珠单抗用于治疗高危早期三阴性乳腺癌：美国临床肿瘤学会指南快速推荐更新
J Clin Oncol. 2022 May 20;40(15):1696-1698. doi: 10.1200/JCO.22.00503. Epub 2022 Apr 13.
9
Systemic Therapy for Melanoma: ASCO Guideline Rapid Recommendation Update.黑色素瘤的全身治疗：美国临床肿瘤学会指南快速推荐更新
J Clin Oncol. 2022 Jul 20;40(21):2375-2377. doi: 10.1200/JCO.22.00944. Epub 2022 Jun 3.
10
Management of Metastatic Renal Clear Cell Cancer: ASCO Guideline Rapid Recommendation Update.转移性肾透明细胞癌的管理：美国临床肿瘤学会指南快速推荐更新
J Clin Oncol. 2023 Nov 20;41(33):5184-5186. doi: 10.1200/JCO.23.01977. Epub 2023 Oct 9.

引用本文的文献

1
Nanosensitizer-assisted sonodynamic therapy for breast cancer.纳米敏化剂辅助的乳腺癌声动力治疗
J Nanobiotechnology. 2025 Apr 7;23(1):281. doi: 10.1186/s12951-025-03311-3.
2
Treatment patterns and outcomes in HER2-low metastatic breast cancer patients previously treated with chemotherapy: a US real-world cohort study.既往接受过化疗的HER2低表达转移性乳腺癌患者的治疗模式与结局：一项美国真实世界队列研究
Breast Cancer Res Treat. 2025 Jun;211(2):351-362. doi: 10.1007/s10549-025-07649-y. Epub 2025 Mar 25.
3
Dynamic HER2-low status among patients with triple negative breast cancer (TNBC) and the impact of repeat biopsies.
三阴性乳腺癌（TNBC）患者中HER2低表达状态的动态变化及重复活检的影响
NPJ Breast Cancer. 2025 Mar 11;11(1):27. doi: 10.1038/s41523-025-00741-y.
4
Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01.达泊托单抗德鲁替康与化疗用于既往治疗过的不可切除/转移性激素受体阳性、人表皮生长因子受体2阴性乳腺癌的疗效比较：TROPION-Breast01研究的主要结果
J Clin Oncol. 2025 Jan 20;43(3):285-296. doi: 10.1200/JCO.24.00920. Epub 2024 Sep 12.
5
Breast cancer learning health system: Patient information from a data and analytics platform characterizes care provided.乳腺癌学习型健康系统：来自数据与分析平台的患者信息可描述所提供的护理情况。
Learn Health Syst. 2024 Feb 13;8(3):e10409. doi: 10.1002/lrh2.10409. eCollection 2024 Jul.
6
Prognostic implications of HER2NEU-low in metastatic breast cancer.HER2NEU 低表达转移性乳腺癌的预后意义。
Cancer Med. 2024 Jan;13(2):e6979. doi: 10.1002/cam4.6979.
7
Systemic Treatment of Patients With Metastatic Breast Cancer: ASCO Resource-Stratified Guideline Q and A.转移性乳腺癌患者的系统治疗：ASCO 资源分层指南问答。
JCO Glob Oncol. 2024 Jan;10:e2300411. doi: 10.1200/GO.23.00411.
8
Systemic Treatment of Patients With Metastatic Breast Cancer: ASCO Resource-Stratified Guideline.转移性乳腺癌患者的系统治疗：ASCO 资源分层指南。
JCO Glob Oncol. 2024 Jan;10:e2300285. doi: 10.1200/GO.23.00285.
9
Retrospective study to estimate the prevalence and describe the clinicopathological characteristics, treatments received, and outcomes of HER2-low breast cancer.回顾性研究估计 HER2 低表达乳腺癌的患病率，并描述其临床病理特征、接受的治疗及结局。
ESMO Open. 2023 Aug;8(4):101615. doi: 10.1016/j.esmoop.2023.101615. Epub 2023 Aug 8.
10
Survival Outcomes in Patients With Hormone Receptor-Positive Metastatic Breast Cancer With Low or No ERBB2 Expression Treated With Targeted Therapies Plus Endocrine Therapy.激素受体阳性、低表达或无表达 ERBB2 的转移性乳腺癌患者接受靶向治疗联合内分泌治疗的生存结局。
JAMA Netw Open. 2023 May 1;6(5):e2313017. doi: 10.1001/jamanetworkopen.2023.13017.